TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Incidence of post-spinal hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean maximum increase in INR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Quantitative sensory test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in daily minutes of non-sedentary physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to entry in laparoscopic surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Occurrence of Clavien and Dindo complication ≥ grade II
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Maternal HIV Viral Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Maternal Antiretroviral (ART) Adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Prevention of Mother-to-child-transmission (PMTCT) Care Retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance between treatment location and brain target
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comparison of actual dwell time to intended dwell time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to diagnosis of acute graft versus host disease (aGVHD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to diagnosis of relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of Procedure Related Serious Adverse Events (SAE) at 30 Days Post-treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Device Related Serious Adverse Events (SAE) at 30 Days Post-treatment
Endpoint domain: Adverse events/effects
Primary endpoint: total body nevus count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pharmacodynamic effect of food intake vs fasting on AZD1722
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of a shared care survivorship care plan
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of a shared care survivorship care plan
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence Rates of Acute Liver Injury (ALI)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence Rates of Acute Kidney Injury (AKI)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence Rates of Diabetic Ketoacidosis (DKA)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence Rates of Severe Complications of Urinary Tract Infections (UTIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence Rates of Genital Infections in Males (GIM)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence Rates of Genital Infections in Females (GIF)
Endpoint domain: Adverse events/effects
Primary endpoint: Alveolar dimensional loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mobility measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of MRI Gd-enhanced T1-weighted lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in HAMD-17 Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Annualized Lesion Enlargement Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of plasma TP53 mutation detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Specificity of plasma TP53 mutation detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of major malformation overall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of cardiovascular malformation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of nervous system malformation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of gastrointestinal system malformation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of genital malformation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of urinary malformation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants Reporting Local Reactogenicity Signs and Symptoms of the Left Arm
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms During the Boost Regimen
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Env-specific IgG Responses for gp120, gp41, V1/V2, and the IDR of gp41 at 2 Weeks After Each Boost
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sensitivity and specificity of CCE compared to CTC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biliary fistula rate
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Prevalence of Abnormal 99mTc-rhAnnexin V-128 SPECT/CT Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of the Disease (Total Symptom Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acid-base status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum chloride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tamsulosin Cmax,ss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tamsulosin AUCτ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Best-Corrected Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in concentration of serum malondialdehyde
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in ATPase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in concentration of total antioxidant capacity (TAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of sports-related lower extremity injuries
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of postoperative delirium
Endpoint domain: Adverse events/effects
Primary endpoint: flow mediated arterial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of triglycerides from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline in Heart Rate by 12-Lead ECG in Paper and Digital Recordings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Visual Analogue Scale (VAS) Pain Score for Site Reaction Pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Prosthetic Dislocation
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline to Treatment in Hemoglobin HbA1c (A1C) at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline to Treatment in Fasting Plasma Glucose (FPG) at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: resolution of uveal effusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adverse fetal outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Time to Radiological Progression-Free Survival (PFS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulse rate monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep pattern monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stress level monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent reduction in immunodominant Donor Specific Antibody (iDSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in Inhibitory Performance: Stroop Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in Neuroelectrical Activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical status of the patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of dose-limiting toxicities of HA-1 T cell receptor (TCR) T cells
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of plasma levels of noncarboxylated MGP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction of plasma levels of noncarboxylated osteocalcin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of plasma levels of inactive prothrombin (PIVKA-II)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Airway mechanics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cardiovascular anatomy and physiology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rates of neurological impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rates of disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean Ex-Vivo Advancing Contact Angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glutathione redox status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Father/Co-parent relationship quality
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Child well-being
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Economic Self-sufficiency
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: RNA and protein measures from esophageal biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative frequency of TCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor and participation assessments score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timocco virtual reality system score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality of patients supported with ECMO
Endpoint domain: Mortality/survival
Primary endpoint: Total fluorescein corneal staining score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary ocular discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ischemic stroke event
Endpoint domain: Mortality/survival
Primary endpoint: General Well-being as Assessed by SF-36 Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Microscopic changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cardiovascular death/re-hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: All-cause mortality/re-hospitalization treatment failure
Endpoint domain: Mortality/survival
Primary endpoint: Heart failure mortality/re-hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Ablation Success - Elimination of Clinical Arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUCt, AUCinf and Cmax of Exemestane 25 mg tablets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients who are disease free
Endpoint domain: Mortality/survival
Primary endpoint: Sustainability of WASH-related behaviours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental well-being measures
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Thoughts and emotions of patients
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Muscle satellite cell proliferation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle satellite cell differentiation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MACE (composite of cardiac death, myocardial infarction and definite/probable stent thrombosis)
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants with dose limiting toxicities (DLTs) while receiving dalotuzumab alone
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with DLTs while receiving dalotuzumab and ridaforolimus combination therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Renal function: estimated glomerular filtration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of procedure and device-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Aphasia Communication Outcome Measure (ACOM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Boston Naming Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Fat mass by DXA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lean mass by DXA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone mass by DXA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Opioid Dose (Morphine-equivalent Dose in mg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percent change in Contact Dermatitis Severity Index (CDSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Significant coronary artery disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acetylcholine Vascular Reactivity Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence and severity of acute graft versus host disease
Endpoint domain: Adverse events/effects
Primary endpoint: Toxicity of conditioning regimen
Endpoint domain: Adverse events/effects
Primary endpoint: maximum tolerated dose of AMG 232
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate and extent of Nikkomycin Z absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: POPQ points AA, BA, Ap, or Bp at less than 0 cm from the hymen or point C descends less than 1/3 of TVL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of re-treatment for prolapse at 2 years
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Negative response to bulge sensation in the vaginal area
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of 50% Responders For All Seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Percentage of Participants With Objective Response in the CNS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of major birth defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in Cholesterol LDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dihydrotestosterone-to-Testosterone Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Free Testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Wounds presence (size and grading using the Wagner scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: monoamine oxidase markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procalcitonin levels for diagnosing neonatal sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Adult Participants Experiencing ≥1 Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric Mean Concentration (GMC) of Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibodies at 1 Month Postdose 3 (PD3) in Infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of oral and tonsillar HPV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Subjects Showing a Reduction in PSA Value (Prostate Specific Antigen) From Baseline to 6-Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse events (AEs) probably or possibly related to ReposMBZ
Endpoint domain: Adverse events/effects
Primary endpoint: Tumour response: CT/MRI assessed according to RECIST 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Blood concentration of oral galactose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of LTC residents on vitamin D
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: T cell activation in adipose tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Experiencing any Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Experiencing any Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: androgens levels after stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Apnea-Hypopnea Index (AHI) Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Eligible Caregivers Who Agree to Participate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Eligible Caregivers Who Participate in Each Session
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Correlation of PET scan parameters with biopsy findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Blepharospasm Disability Index (BSDI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Biopsy-Proven Acute Rejections
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of education and training program implementation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: CCST Test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plasma concentrations of dexmedetomidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plasma concentrations of fentanyl
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plasma concentrations of morphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plasma concentrations of midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Eyes With Anterior Chamber Cell Grade 0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Incidence of Acute Graft Versus Host Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement of Erectile Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Onset of Drug Effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Second successful intercourse
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: number of violent or threatening incidents
Endpoint domain: Adverse events/effects
Primary endpoint: Estimate malignant neoplasm (SMN) risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Return of vocal fold function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Viral Response (SVR24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Clinically relevant non major bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Eastern Cooperative Oncology Group Performance Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lumbar structure assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Chemical Concentration in deciduous teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Center for Epidemiologic Studies Depression (CED-D) Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in work readiness skills
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: IBS severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes